title: Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.
abstract: OBJECTIVE
  To assess the anatomical and functional efficacy of ranibizumab on vascularized pigment epithelial detachment (V-PED) secondary to neovascular age-related macular degeneration (nAMD).
  
  
  METHODS
  One hundred and nine patients (116 eyes) were retrospectively selected from medical records of 2097 patients who benefited from intravitreal injection between January 2011 and June 2013 in a tertiary-care University-based Department of Ophthalmology. Inclusion criteria were: nAMD, treatment-naive eyes, presence of V-PED higher than 250 μm, intravitreal ranibizumab with a loading phase, followed by a pro-re-nata regimen, and 1-year follow-up. Baseline characteristics and type of choroidal neovascularization (CNV) were analyzed. PED height, central macular thickness (CMT) and best-corrected visual acuity (BCVA, logMAR) were measured at baseline, months 3, 6 and 12.
  
  
  RESULTS
  CNV was of type 1 in 91 eyes (78.4 %), type 2 in seven (6 %), type 3 in six (5.2 %), and polypoidal choroidal vasculopathy in 12 (10.3 %). Mean CMT at baseline was 572.1 μm and decreased to 396.6 μm (p < 0.0001) at 12 months. Mean height of PED was 458.2 μm at baseline and 306.8 μm (p < 0.0001) at 12 months. Mean BCVA improved from 0.46 at baseline to 0.39 at 12 months (p = 0.013).
  
  
  CONCLUSIONS
  Treatment with ranibizumab improved visual and anatomical outcome in nAMD patients with V-PED.
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Chevreaud
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France. oubraham@icloud.com.
authors.forename: Hassiba
authors.initials: H
authors.lastname: Oubraham
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France.
authors.forename: Salomon Y
authors.initials: SY
authors.lastname: Cohen
authors.affiliation: Clinical Research Center, Centre Hospitalier Intercommunal, Creteil, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Jung
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France.
authors.forename: Rocio
authors.initials: R
authors.lastname: Blanco-Garavito
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France.
authors.forename: Farah
authors.initials: F
authors.lastname: Gherdaoui
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods*; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000008:administration & dosage*; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy*; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Age related macular degeneration; Anti-vascular endothelial growth factor; Pigment epithelial detachment; Ranibizumab